Osimertinib + Chemo Improves Progression-Free Survival in Advanced NSCLC
Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.